NCT06666283View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 27, 2025

Primary Completion Date

September 25, 2025

Study Completion Date

September 25, 2025

Conditions
Diabetic Kidney Disease
Interventions
DRUG

AP303 150μg

AP303 Tablet 150μg QD

DRUG

Placebo 150μg

Placebo Tablet 150μg QD

Trial Locations (1)

100009

RECRUITING

Peking University First Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Alebund Pharmaceuticals

INDUSTRY

NCT06666283 - A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients | Biotech Hunter | Biotech Hunter